The civic record
Read. Follow. Verify.Ensuring Access to Lower-Cost Medicines for Seniors Act
Last action · April 16, 2026: Read twice and referred to the Committee on Finance.Sponsors: James Lankford and 2 others
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
This bill requires Medicare prescription drug plans to include lower-cost generic and drugs on their approved drug lists (formularies) starting in 2028. It also mandates that these plans create specific cost-sharing tiers with lower copayments for these cheaper alternatives compared to brand-name drugs.
Starting January 1, 2028, Medicare Part D plans must prioritize lower-cost generic and medications in their coverage and pricing structures, potentially reducing out-of-pocket costs for seniors.
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Medicare Part D enrollees
Seniors and others on Medicare will have access to lower-cost generic and biosimilar drugs with reduced cost-sharing requirements.
PDP sponsors and Medicare Advantage organizations
These organizations must restructure their drug formularies and cost-sharing tiers to comply with the new inclusion and pricing mandates.
Key Facts
- Effective January 1, 2028, Medicare Part D plans must include generic drugs and biosimilar products on their formularies if they are cheaper than the reference brand-name drug.
- Plans are prohibited from applying more restrictive access rules (like prior authorization or step therapy) to these lower-cost generics than they apply to the brand-name versions.
- Plans must create at least one cost-sharing tier exclusively for generic and biosimilar drugs.
- Copayments for the generic-only tier must be at least $20 lower than the lowest brand-name drug tier, or provide a similar actuarial reduction if using coinsurance.
Show all 7 facts
- Plans with a 'specialty tier' must create a second specialty tier exclusively for high-cost generic and biosimilar drugs.
- The Secretary of Health and Human Services will establish uniform requirements for determining which drugs qualify and how formulary changes are implemented.
- Determinations for formulary inclusion must be reviewed and updated on a quarterly basis during the plan year.
Frequently Asked Questions
When would these changes take effect?
Will my Medicare plan be allowed to make it harder to get a generic drug than a brand-name drug?
How much will I save on copayments?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
2 actions- Apr 16, 2026SenateCommitteeRead twice and referred to the Committee on Finance.
- Apr 16, 2026SenateIntroducedIntroduced in Senate
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Mandatory Tiering
The bill shifts from allowing plans to design their own cost-sharing tiers to mandating specific 'generic-only' tiers with defined price gaps.
Connected Entities
Sources
www.congress.gov
Analysis Score
0–100- Significance75How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools